Importance of selected inhaler characteristics and acceptance of a new breath-actuated powder inhalation device

Journal of Asthma

Volumn 34, Issue 3, 1997, Pages 249-253

  Nielsen, Kirsten ^a   Okamoto, Lynn ^a   Shah, Tushar ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIASTHMATIC AGENT; FLUTICASONE PROPIONATE;

ARTICLE; ASTHMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; HUMAN; INHALATIONAL DRUG ADMINISTRATION; INHALER; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; PATIENT COMPLIANCE; PATIENT SATISFACTION; POWDER INHALER; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL;

EID: 0030987322     PISSN: 02770903     EISSN: None     Source Type: Journal    
DOI: 10.3109/02770909709068196     Document Type: Article

References (7)

1. Horn CR, Clark TJH, Cochrane GM: Compliance with inhaled therapy and morbidity from asthma. Respir Med 84:67-70 (1990).
2. Crompton GK: Problems patients have using pressurised aerosol inhalers. Eur J Respir Dis 119:101-104 (1982).
3. Wardman AG, Cooke NJ: Bronchodilator therapy in general practice - What are the problems? Practitioner 229:631-635 (1985).
4. Chapman KR, Love L, Brubaker H: A comparison of breath-actuated and conventional metered-dose inhaler inhalation techniques in elderly subjects. Chest 104:1332-1337 (1993).
5. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis 136:225-244 (1987).
6. Gagnon JP, Boyer JG, Broome M: Corporate image: the importance of performance. Pharm Exec, 38-43 (January 1988).
7. Lawrence M, Taunton MA, Ziering W, et al: Efficacy of inhaled fluticasone propionate in asthma occurs via topical rather than systemic effect. J Allergy Clin Immunol 95(1, part 2):311 (1995).